Catalyst’s scientists focused on creating improved, next-generation, pro-coagulant proteases and novel proteases that cleave targets in the complement cascade
Improving Protease Drugs
Catalyst created improved protease variants using a rational design strategy. In this process, a small number of amino acids in a given protease are substituted in an iterative fashion with different amino acids to improve a molecule’s biological properties. This approach led to product candidates that have the potential to be improved versions of Factor VIIa, Factor IX, and Factor Xa that may have many important and differentiated advantages including higher activity, longer duration of action, and improved safety.
Creation of Novel Protease Drugs
Catalyst has developed and optimized a propriety method to create novel proteases that currently make up part of our partnering portfolio, including our anti-C3 proteases including CB 2782 for delayed graft function (DGF) and the leads in our dry age-related macular degeneration (AMD) program. In September 2016, Catalyst reduced resources deployed towards its anti-complement research programs and all related research activities were discontinued. Catalyst intends to explore licensing opportunities for its anti-complement programs in DGF and Dry AMD.